With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: It has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, while the trial group with Merck’s drug had only 7% hospitalized and zero deaths.

This appears to be just the tip of the iceberg; Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Latest

irish whiskey barrels
E.U. Whiskey Tariffs Are Lifted, But the Industry is Still On the Rocks
January 21, 2022
  The whiskey market is eager for a return to form. In 2018, in response to the U.S. steel and aluminum tariffs targeting the E.U. and ordered by former President Donald Trump, the European Read more
Material Signs: Introduction to the World of Optics
January 21, 2022
Doctors Scott Carney, chief science and technology officer at Optica, Kate Medicus, CEO at Ruda-Cardinal, and Alexis Vogt, endowed chair and professor of optics at Monroe Community College, joined Host Tyler Read more
What Defines "Success" for Safety Personnel?
What Defines “Success” for Safety Personnel?
January 21, 2022
The Safety Justice League is back and refreshed after a much-needed, restful holiday season. Jason squared (Jason Maldonado and Jason Lucas) joined Host Abby Ferri to dive into what success looks like Read more